The cause of multiple sclerosis (MS) is not known and the mechanism of interferon-beta, a disease-modifying treatment, is not well-understood. We studied gene expression in plasmacytoid dendritic cells (pDCs), antigen-presenting cells implicated in MS pathogenesis. PDCs were separated from healthy donors and MS patients at two time points: before and after initiation of treatment with interferon-beta. Expression of selected MS-linked and interferon-beta-regulated genes was validated with single assays. We have identified 60 genes which were abnormally expressed in MS patients and were corrected after treatment. These genes could be studied as potential MS biomarkers and possible therapeutic targets in MS.
Introduction
Multiple sclerosis (MS) is an immune-mediated chronic inflammatory and neurodegenerative disease of the central nervous system. The etiology of MS is unknown. Multiple genetic and environmental factors have been implicated in the disease pathogenesis. Global gene expression profiling analysis in relatively homogenous cell populations, such as tumor cells, has been proven a powerful tool to identify abnormally expressed genes linked to disease pathogenesis (Ring and Ross, 2002; Chen et al., 2003) . Gene expression studies done in patients with MS have used mostly a heterogeneous population of peripheral blood mononuclear cells (PBMC) (Bomprezzi et al., 2003; Mandel et al., 2004; Satoh et al., 2005; Gandhi et al., 2010) or postmortem autopsy samples comprised of several cell subsets with different morphology, gene expression profile, and function. As a result, the gene expression changes in key cell subsets involved in immunopathogenesis of MS, e.g., dendritic cells or B cells, could be easily masked/diluted by changes in other more abundant PBMC subsets.
DNA viruses such as EBV and herpes zoster virus have been implicated in MS pathogenesis (Haahr and Hollsberg, 2006; Serafini et al., 2007; Kang et al., 2011) . Plasmacytoid dendritic cells (pDCs) are involved in early recognition of viral pathogens, express the highest level of Toll-like receptor 9 (TLR9) compared to other PBMC subsets, and strongly contribute to innate and adaptive immune responses. TLR9 recognizes unmethylated CpG dinucleotides in bacterial and viral DNA sequences. Upon activation, pDCs secrete multiple cytokines such as interferons and promote T cell responses (Rissoan et al., 1999; Cella et al., 2000; Kuwana et al., 2001; Gilliet and Liu, 2002) . The function of pDCs is impaired in a number of human disorders including HIV infection, systemic lupus erythematosus, and cancer; conditions associated with abnormal immune responses to self-antigens and pathogens (Vallin et al., 1999; Farkas et al., 2001; Feldman et al., 2001; Zou et al., 2001; Chehimi et al., 2002; Munn et al., 2004) . PDCs have been found in the brain and cerebrospinal fluid (CSF) of MS patients (Lande et al., 2008; Longhini et al., 2011) and the concentration of pDCs is increased in the CSF of MS patients during an MS exacerbation (Longhini et al., 2011) . One of the factors responsible for pDC recruitment to the CSF is Fms-like tyrosine kinase 3 ligand, which is constitutively expressed in the brain (Curtin et al., 2006) and is involved in the pathogenesis of experimental autoimmune encephalomyelitis, an animal model of MS (Greter et al., 2005; Whartenby et al., 2005) .
IFN-beta 1a and 1b are FDA-approved disease modifying treatments (DMT) for MS. IFN-beta has multiple anti-viral and immunomodulatory mechanisms, including modulation of cell proliferation and apoptosis (Noronha et al., 1993; Sharief et al., 2001) , expression E-mail address: kbalashov@yahoo.com (K.E. Balashov).
